Immune-based therapeutics: Scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual

Clinical Infectious Diseases

Volumn 17, Issue 4, 1993, Pages 749-771

  Stein, Daniel S ^a   Timpone, Joseph G ^a   Gradon, Jeremy D ^a,b   Schnittman, Steven M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INDOMETACIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; RIBAVIRIN; THYMOPENTIN; THYMOSIN ALPHA1; THYMOSIN FRACTION 5; THYMUS HORMONE; TUMOR NECROSIS FACTOR;

ADOPTIVE IMMUNOTHERAPY; APHERESIS; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; VACCINATION;

ADULT; AIDS VACCINES; ANTIBODIES, MONOCLONAL; BLOOD COMPONENT REMOVAL; CHILD; CHILD, PRESCHOOL; CYTOKINES; HIV INFECTIONS; HIV-1; HUMAN; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INFANT; INFANT, NEWBORN; THYMUS HORMONES;

EID: 0027361617     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/17.4.749     Document Type: Article

References (195)

1. Stiehm ER, Ashida E, Kim KS, Winston DJ, Haas A, Gale RP. Intravenous immunoglobulins as therapeutic agents. Ann Intern Med 1987;107:367-82.
2. Robert-Guroff M, Roilides E, Muldoon R, et al. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV infected children: correlation with clinical status and prognostic value. J Infect Dis 1993;167:538-46.
3. European Collaborative Study. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991;337:253-60.
4. Goedert JJ, Duliêge AM, Amos CI, Felton S, Biggar RJ. High risk of HIV-1 infection for first born twins. The International Registry of HIV-Exposed Twins. Lancet 1991;338:1471-5.
5. Ljunggren K, Moschese V, Broliden P-A, et al. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990;161:198-202.
6. Oleske JM, Connor EM, Bobila R, et al. The use of IVIG in children with AIDS [abstract]. Vox Sang 1987;52:172.
7. Hague RA, Yap PL, Mok JYQ, et al. Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment. Arch Dis Child 1989;64:1146-50.
8. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;325:73-80.
9. Mofenson LM, Moye J Jr, Bethel J, Hirschhorn R, Jordan C, Nugent R, for the National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ count of 0.20 X 109/L or more: effect on viral, opportunistic, and bacterial infections. JAMA 1992;268:483-8.
10. Mofensen LM, Moye J, Bethel J, for the NICHD IVIG Clinical Trial Study Group. Effect of intravenous immunoglobulin (IVIG) on CD4+ cell decline in HIV-infected children in a clinical trial of IVIG prophylaxis [abstract no PoB 3449]. In: Program and abstracts: VIII International Conference on AIDS (Amsterdam). Amsterdam: Congrex Holland BV, 1992.
11. Spector SA, Sacks H, Wara D, et al. Results of ACTG 051: a double blind, placebo-controlled trial to evaluate intravenous immunoglobulin in children with symptomatic HIV infection receiving zidovudine [abstract no 103]. In: Program and abstracts of the 30th annual meeting of the Infectious Diseases Society of America. Washington, DC: Infectious Diseases Society of America, 1992.
12. Brunkhorst U, Stiimer M, Willers H, Deicher H, Schedel I. Efficacy of intravenous immunoglobulins in patients with advanced HIV-1 infection. A randomized clinical study. Infection 1990;18:86-90.
13. Williams PE, Thompson C, Yap PL, Brette RP. Controlled study of intravenous IgG therapy for HIV-infected adults with recurrent bacterial infections [letter]. Vox Sang 1991;60:126-7.
14. De Simone C, Antonaci S, Chirigos M, et al. Report of the symposium on the use of intravenous gammaglobulin in adults infected with the human immunodeficiency virus. J Clin Lab Anal 1990;4:313-7.
15. Cummins LM, Weinhold KJ, Matthews TJ, et al. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 1991;77:1111-7.
16. Karpas A, Hill F, Youle M, et al. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci USA 1988;85:9234-7.
17. Karpas A, Gray J, Byron N, et al. Passive immunization in ARC and AIDS. Biotherapy 1990;2:159-72.
18. Jackson GG, Perkins JT, Rubenis M, et al. Passive immunoneutralisation of human immunodeficiency virus in patients with advanced AIDS. Lancet 1988;2:647-52.
19. Vittecoq D, Mattlinger B, Barre-Sinoussi F, et al. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis 1992;165:364-8.
20. HIV passive hyperimmune therapy trial indicates safety and efficacy. Antiviral Agents Bulletin 1992;5:135-8.
21. Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, Sodroski J. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 1991;65:6188-93.
22. Gowland P, Gunthard H, Schupbach J, et al. Phase I/IIA clinical studies of a chimeric mouse-human monoclonal antibody to HIV-1 gp120 [abstract no PoB 3445]. In: Program and abstracts: VIII International Conference on AIDS (Amsterdam). Amsterdam: Congrex Holland BV, 1992.
23. Kiprov DD, Lippert R, Miller RG, et al. The use of plasmapheresis, lymphocytapheresis and Staph protein-A immunoadsorption as an immunomodulatory therapy in patients with AIDS and AIDS-related conditions. J Clin Apheresis 1986;3:133-9.
24. Oates KK, Sztein MB, Goldstein AL. Mechanism of action of the thymosins: modulation oflymphokines, receptors, and T-cell differentiation antigens. Immunol Ser 1989;45:273-88.
25. Baxevanis CN, Frillingos S, Seferiadis K, et al. Enhancement of human T lymphocyte function by prothymosin alpha: increased production ofinterleukin-2 and expression ofinterleukin-2 receptors in normal human peripheral blood T lymphocytes. Immunopharmacol Immunotoxicol 1990;12:595-617.
26. Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol 1990;12:19-29.
27. Baxevanis CN, Anastasopoulos E, Reclos GJ, Papamichail M. Prothymosin- a enhances HLA-DR antigen expression on monocytes from patients with multiple sclerosis. J Neuroimmunol 1990;27:141-7.
28. Conteas CN, Mutchnick MG, Palmer KC, et al. Cellular levels of thymosin immunoreactive peptides are linked to proliferative events: evidence for a nuclear site of action. Proc Natl Acad Sci USA 1990;87:3269-73.
29. Clinton M, Graeve L, El Dorry H, Rodriguez-Boulan E, Horecker BL. Evidence for nuclear targeting of prothymosin and parathymosin synthesized in situ. Proc Natl Acad Sci USA 1991;88:6608-12.
30. RosOn E, Gallego R, Garcia-Caballero T, Heimer EP, Felix AM, Dominguez F. Prothymosin alpha expression is associated to cell division in rat testis. Histochemistry 1990;94:597-9.
31. Sburlati AR, Manrow RE, Berger SL. Prothymosin a antisense oligomers inhibit myeloma cell division. Proc Natl Acad Sci USA 1991;88:253-7.
32. Bustelo XR, Otero A, GOmez-Marquez J, Freire M. Expression of the rat prothymosin a gene during T-lymphocyte proliferation and liver regeneration. J Biol Chem 1991;266:1443-7.
33. Clauss IM, Wathelet MG, Szpirer J, et al. Human thymosin-13 4/6-26 gene is part of a multigene family composed of seven members located on seven different chromosomes. Genomics 1991;9:174-80.
34. GOrnez-Marquez J, Dosil M, Segade F, et al. Thymosini3 4 gene: preliminary characterization and expression in tissues, thymic cells, and lymphocytes. J Immunol 1989;143:2740-4.
35. Safer D, Elzinga M, Nachmias VT. Thymosin,34 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem 1991; 266:4029-32.
36. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991;14:409-15.
37. Davis GL. Treatment of chronic hepatitis B [editorial]. Hepatology 1991;14:567-9.
38. Faist E, Markewitz A, Fuchs D, et al. Immunomodulatory therapy with thymopentin and indomethacin: successful restoration of in terleukin-2 synthesis in patients undergoing major surgery. Ann Surg 1991;214:264-75.
39. Dumann H, Meuer SC, Renschin G, KOhler H. Influence of thymopentin on antibody response and monocyte and T cell function in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 1990;55:136-40.
40. Beyer WEP, Noordzij TC, Kramer P, et al. Effect of immunomodulator thymopentin on impaired seroresponse to influenza vaccine in patients on haemodialysis. Nephron 1990;54:296-301.
41. Gravenstein S, Duthie EH, Miller BA, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one: a double-blind placebo-controlled clinical study. J Am Geriatr Soc 1989;37:1-8.
42. Silvestris F, Gernone A, Frassanito MA, Dammacco F. Immunologic effects of long-term thymopentin treatment in patients with HIVinduced lymphadenopathy syndrome. J Lab Clin Med 1989; 113:139-44.
43. Beall G, Kruger S, Morales F, et al. A double-blind, placebo-controlled trial of thymostimulin in symptomatic HIV-infected patients. AIDS 1990;4:679-81.
44. Conant MA, Calabrese LH, Thompson SE, et al. Maintenance of CD4+ cells by thymopentin in asymptomatic HIV-infected subjects: results of a double-blind, placebo-controlled study. AIDS 1992;6:1335-9.
45. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
46. Kennedy PS, Scolaro M, Blayney D. Failure of combined antiviral and immune modulation therapy to alter clinical and biological parameters in acquired immunodeficiency syndrome (AIDS) patients [abstract no A17]. In: Proceedings of the annual meeting of the American Society of Clinical Oncology. Philadelphia: WB Saunders, 1989:8.
47. Witherspoon RP, Sullivan KM, Lum LG, et al. Use of thymic grafts or thymic factors to augment immunologic recovery after bone marrow transplantation: brief report with 2 to 12 years' follow-up. Bone Marrow Transplant 1988;3:425-35.
48. Danner SA, Schuurman H-J, Lange JMA, et al. Implantation of cultured thymic fragments in patients with acquired immunodeficiency syndrome. Arch Intern Med 1986;146:1133-6.
49. Dupuy J-M, Gilmore N, Goldman H, et al. Thymic epithelial cell transplantation in patients with acquired immunodeficiency syndrome: evidence for infection by HIV-1 of newly differentiated T cells at the site of transplantation. Thymus 1991;17:205-18.
50. Pahwa R, Pahwa S, Good RA, Incefy GS, O'Reilly RJ. Rationale for combined use of fetal liver and thymus for immunological reconstitution in patients with variants of severe combined immunodeficiency. Proc Natl Acad Sci USA 1977;74:3002-5.
51. Touraine J-L, Roncarolo MG, Royo C, Touraine F. Fetal tissue transplantation, bone marrow transplantation and prospective gene therapy in severe immunodeficiencies and enzyme deficiencies. Thymus 1987;10:75-87.
52. Ammann AJ. Biologic and immunomodulating factors in the treatment of pediatric acquired immunodeficiency syndrome. Pediatr Infect Dis J 1990;9:894-904.
53. Schwartz DH, Merigan TC. Interleukin-2 in the treatment of HIV disease. Biotherapy 1990;2:119-36.
54. Lane HC, Siegel JP, Rook AH, et al. Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J Biol Response Mod 1984;3:512-6.
55. Ernst M, Kern P, Flad H-D, Ulmer AJ. Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC). J Clin Immunol 1986;6:170-81.
56. Volberding P, Moody DJ, Beardslee D, Bradley EC, Wofsy CB. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses 1987;3:115-24.
57. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990;322:959-65.
58. Rosenberg SA, Lotze MT, Mule JJ. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 1988;108:853-64.
59. Penn RL, Nguyen VQ, Specian RD, Stevens P, Berg RD. Interleukin- 2 enhances the translocation of Escherichia coli from the intestines to other organs. J Infect Dis 1991;164:1168-72
60. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin- 2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1991;4:11-23.
61. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993;167:519-25.
62. Teppler H, Kaplan G, Smith K, et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993;167:291-8.
63. Waltes L, Fyfe G, Senechek D, et al. Polyethylene glycol modified interleukin-2 (PEG IL-2) therapy in HIV seropositive individuals [abstract no PuB 7580]. In: Program and abstracts: VIII International Conference on AIDS (Amsterdam). Amsterdam: Congrex Holland BV, 1992.
64. Odeh M. The role of tumour necrosis factor-a in acquired immunodeficiency syndrome. J Intern Med 1990;228:549-56.
65. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1991;163:1 177-84.
66. Landevirta J, Maury CPJ, Teppo A-M, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-91.
67. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;1 14:678-93.
68. Dezube BJ, Pardee AB, Chapman B, et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J Acquir Immune Defic Syndr 1993;6:787-94.
69. Laurence J. Immunology of HIV infection. I. Biology of the interferons. AIDS Res Hum Retroviruses 1990;6:1149-56.
70. Francis ML, Meltzer MS, Gendelman HE. Interferons in the persistence, pathogenesis, and treatment of HIV infection. AIDS Res Hum Retroviruses 1992;8:199-207.
71. Baron S, Tyring SK, Fleischmann WR, et al. The interferons: mechanisms of action and clinical applications. JAMA 1991;266:1375-83.
72. Smith MS, Thresher RJ, Pagano JS. Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon. Antimicrob Agents Chemother 1991;35:62-7.
73. Naso RB, Wu Y-H, Edbauer CA. Antiretroviral effects of interferon: proposed mechanism. J Interferon Res 1982;2:75-96.
74. Tamm I, Wang E, Landsberger F, Pfeiffer L. Interferon modulates cell structure and function. In: Interferons. London: Academic Press, 1982:159-79.
75. Constantoulakis P, Campbell M, Felber BK, Nasioulas G, Afonina E, Pavlakis GN. Inhibition of rev-mediated HIV-1 expression by an RNA binding protein encoded by the interferon-inducible 9-27 gene. Science 1993;259:1314-18.
76. DeStefano E, Friedman RM, Friedman-Kien AE, et al. Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis 1982;146:451-5.
77. Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992;339:453-6.
78. Rossol S, Voth R, Laubenstein HP, et al. Interferon production in Patients infected with HIV-1. J Infect Dis 1989;159:815-21.
79. Lau AS, Read SE, Williams BRG. Downregulation of interferon a but not 7 receptor expression in vivo in the acquired immunodeficiency syndrome. J Clin Invest 1988;82:1415-21.
80. Gendelman HE, Baca LM, Turpin J, et al. Regulation of HIV replication in infected monocytes by IFN-a: mechanisms of viral restriction. J Immunol 1990;145:2669-76.
81. Gendelman HE, Baca LM, Kubrak CA, et al. Induction of IFNa in peripheral blood mononuclear cells by HIV-infected monocytes: restricted antiviral activity of the HIV-induced IFN. J Immunol 1992;148:422-9.
82. Capobianchi MR, DeMarco F, DiMarco P, Dianzani F. Acid-labile human interferon alpha production by peripheral blood mononuclear cells stimulated by HIV-infected cells. Arch Virol 1988;99:9-19.
83. Ho DD, Hartshorn KL, Rota JR, et al. Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro. Lancet 1985;1:602-4.
84. Shirazi Y, Pitha PM. Alpha interferon inhibits early stages of the human immunodeficiency virus type I replication cycle. J Virol 1992;66:1321-8.
85. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. Interferon-a but not AZT suppresses HIV expression in chronically infected cell lines. Science 1989;244:575-7.
86. Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudinesusceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990;34:436-41.
87. Pincus SH, Wehrly K. AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapy. J Infect Dis 1990;162:1233-8.
88. Hartshorn KL, Vogt MW, Chou T-C, et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother 1987;31:168-72.
89. Vogt MW, Durno AG, Chou T-C, et al. Synergistic interaction of 2'3'-dideoxycytidine and recombinant interferon-a-A on replication of human immunodeficiency virus type 1. J Infect Dis 1988;158:379-85.
90. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-a A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 1991;164:646-55.
91. Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983;308:1071-6.
92. Real FX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986;4:544-51.
93. Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100:671-6.
94. Gelmann EP, Preble OT, Steis R, et al. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical response and prognostic parameters. Am J Med 1985;78:737-41.
95. de Wit R, Schattenkerk JKME, Boucher CAB, Bakker PJM, Veenhof KHN, Danner SA. Clinical and virological effects of high-dose recombinant interferon-a in disseminated AIDS-related Kaposi's sarcoma. Lancet 1988;2:1214-7.
96. Lane HC, Kovacs JA, Feinberg J, et al. Anti-retroviral effects of interferon- a in AIDS-associated Kaposi's sarcoma. Lancet 1988; 2:1218-22.
97. Volberding P, Valero R, Rothman J, Gee G. Alpha interferon therapy of Kaposi's sarcoma in AIDS. Ann N Y Acad Sci 1984;437:439-46.
98. Rozenbaum W, Gharakhanian S, Navarette MS, De Sahb R, Cardon B, Rouzioux C. Long-term follow-up of 120 patients with AIDS-related Kaposi's sarcoma treated with interferon alpha-2a. J Invest Dermatol 1990;95(suppl 6):161S-5S.
99. Sawyer LA, Metcalf JA, Zoon KC, et al. Effects of interferon-a in patients with AIDS-associated Kaposi's sarcoma are related to blood interferon levels and dose. Cytokine 1990;2:247-52.
100. Ellis ME, Haeney MR, Craske J, et al. An open study of interferon in HIV-antibody-positive men. AIDS 1989;3:851-3.
101. Groopman JE, Scadden DT. Interferon therapy for Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) [editorial]. Ann Intern Med 1989;1 10:335-7.
102. Safai B, Bason M, Friedman-Birnbaum R, Nisce L. Interferon in the treatment ofAIDS-associated Kaposi's sarcoma: the American experience. J Invest Dermatol 1990;95(suppl 6):166S-9S.
103. Krown SE. Interferon and other biologic agents for the treatment of Kaposi's sarcoma. Hematol Oncol Clin North Am 1991;5:31 1-22.
104. Nair BC, DeVico AL, Nakamura S, et al. Identification of a major growth factor for AIDS Kaposi's sarcoma cells as oncostatin M. Science 1992;255:1430-2.
105. Miles SA, Martinez-Maza O, Rezai A, et al. Oncostatin M as a potent mitogen for AIDS Kaposi's sarcoma-derived cells. Science 1992;255:1432-4.
106. Kovacs JA, Deyton L, Davey R, et al. Combined zidovudine and interferon-a therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;111:280-7.
107. Krown SE, Gold JWM, Niedzwiecki D, et al. Interferon-a with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;112:812-21.
108. Fischl MA, Uttamchandani RB, Resnick L, et al. A phase I study of recombinant human interferon-a2a or human lymphoblastoid interferon- an 1 and concomitant zidovudine in patients with AIDSrelated Kaposi's sarcoma. J Acquir Immun Defic Syndr 1991;4:1-10.
109. Stadler R, Bratzke B, Schaart F, Orfanos CE. Long-term combined rIFN-alpha-2a and zidovudine therapy for HIV-associated Kaposi's sarcoma: clinical consequences and side effects. J Invest Dermatol 1990;95(suppl 6):170S-5S.
110. Interferon Alpha Study Group. A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with AIDS. J Acquir Immun Defic Syndr 1988;1:111-8.
111. Lane HC, Davey V, Kovacs JA, et al. Interferon-a in patients with asymptomatic human immunodeficiency virus (HIV) infection: a randomized placebo-controlled trial. Ann Intern Med 1990; 112:805-11.
112. Berglund O, Engman K, Ehrnst A, et al. Combined treatment of symptomatic human immunodeficiency virus type-1 infection with native interferon-a and zidovudine. J Infect Dis 1991;163:710-5.
113. Edlin BR, Weinstein RA, Whaling SM, et al. Zidovudine-interferon-a combination therapy in patients with advanced human immunodeficiency virus type-1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction. J Infect Dis 1992; 165:793-8.
114. Lane HC, Herpin B, Banks S, et al. Zidovudine vs alpha interferon vs the combination in patients with early HIV infection [abstract no MoB0052]. In: Program and abstracts: VIII International Conference on AIDS (Amsterdam). Amsterdam: Congrex Holland BV 1992.
115. Edlin BR, Clair MH, Pitha PM, et al. In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response. Ann Intern Med 1992;1 17:457-60.
116. Davey RT, Davey VJ, Metcalf JA, et al. A phase I/II trial of zidovudine, interferon-a, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 1991;164:43-52.
117. Schnittman SM, Davey RT, Haneiwich S, Fauci AS, Lane HC. A phase I study of alpha interferon (IFN-a) in combination with interleukin- 2 (IL-2) in patients with HIV infection [abstract]. Clin Res 1992;40:246A.
118. Koech DK, Obel AO, Minowada J, Hutchinson VA, Cummins JM. Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1). Mol Biother 1990;2:91-5.
119. Kaiser G, Jaeger H, Birkmann J, Poppinger J, Cummins JM, Gallmeier WM. Low-dose oral natural human interferon-a in 29 patients with HIV-1 infection: a double-blind, randomized, placebocontrolled trial. AIDS 1992;6:563-9.
120. Hulton MR, Levin DL, Freedman LS. Randomized placebo-controlled, double blind study of low dose oral interferon-a in HIV-1 antibody positive patients. J Acquir Immun Defic Syndr 1992;5:1084-90.
121. Abrams D, Cotton D, Mayer K, eds. AIDS/HIV treatment directory. Vol 5. New York: American Foundation for AIDS Research, 1992:12-3.
122. U.S. Public Health Service. Press release. Bethesda, MD: National Institutes of Health, 27 April 1992.
123. Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB. Human alpha- and beta-interferon but not gamma- suppresses the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res 1986;6:143-52.
124. Hartshorn KL, Neumeyer D, Vogt MW, Schooley RT, Hirsch MS. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res Hum Retroviruses 1987;3:125-33.
125. Miles SA, Wang H, Cortes E, Carden J, Marcus S, Mitsuyasu RT. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS): a phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections. Ann Intern Med 1990;112:582-9.
126. Lane HC, Davey RT, Sherwin SA, et al. A phase I trial of recombinant human interferon-y in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Immunol 1989;9:351-61.
127. Heagy W, Groopman GE, Schindler J, Finberg R. Use of IFN-gamma in patients with AIDS. J Acquir Immun Defic Syndr 1990;3:584-90.
128. Agosti JM, Coombs RW, Collier AC, et al. A randomized, doubleblind, phase I/II trial of tumor necrosis factor and interferongamma for treatment of AIDS-related complex (protocol 025 from the AIDS Clinical Trials Group). AIDS Res Hum Retroviruses 1992;8:581-7.
129. Shearer GM, Bernstein DC, Tung KSK, et al. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol 1986;137:2514-21.
130. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328:345-8.
131. Wahren B, Morfeldt-Mansson L, Biberfeld G, et al. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987;61:2017-23.
132. Walker BD, Flexner C, Paradis TJ, et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 1988;240:64-6.
133. Ahearne PM, Matthews TJ, Lyerly HK, White GC, Bolognesi DP, Weinhold KJ. Cellular immune response to viral peptides in patients exposed to HIV. AIDS Res Hum Retroviruses 1988;4:259-67
134. Koenig S, Earl P, Powell D, et al. Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1 infected individual. Proc Natl Acad Sci USA 1988;85:8638-42.
135. Culmann B, Gomard E, Kieny M-P, et al. An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules. Eur J Immunol 1989;19:2383-6.
136. Riviere Y, Tanneau-Salvadori F, Regnault A, et al. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol 1989;63:2270-7.
137. Koenig S, Fuerst TR, Wood LV, et al. Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. J Immunol 1990;145:127-35.
138. Tsubota H, Lord CI, Watkins DI, Morimoto C, Letvin NL. A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J Exp Med 1989;169:1421-34.
139. Walker CM, Moody DJ, Stites DP, Levy JA. CD8 + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-6.
140. Plata F, Dadaglio G, Chenciner N, et al. Cytotoxic T lymphocytes in HIV-induced disease: implications for therapy and vaccination. Immunodefic Rev 1989;1:227-46.
141. Mawle AC, Ridgeway MR, Kieny M-P, Lifson AR. CTL response to p24 (gag) in long-term asymptomatic seropositive individuals infected with HIV-1 [abstract no S.A. 254]. In: Program and abstracts: VI International Conference on AIDS (San Francisco). 1990.
142. Luzuriaga K, Koup RA, Pikora CA, Brettler DB, Sullivan JL. Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr 1991;119:230-6.
143. Pantaleo G, DeMaria A, Koenig S, et al. Selective loss of HIV-specific cytolytic activity in patients with AIDS despite a normal broad cytolytic function. HIV-specific CTL belong to the CD8 ±DR+ subset with decreased clonogenic potential [abstract no S.A. 255]. In: Program and abstracts: VI International Conference on AIDS (San Francisco). 1990.
144. Pantaleo G, Koenig S, Baseler M, Lane HC, Fauci AS. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS: expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J Immunol 1990;144:1696-704.
145. DeMaria A, Colombini S, Pantaleo G, et al. Lysis of HIV-1 infected target cells by HIV-specific CD + cytotoxic T-lymphocytes results in infection of the effector cells [abstract no TU.A.13]. In: Program and abstracts: VII International Conference on AIDS (Florence). Rome: Institute Superiore di Sanita, 1991.
146. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
147. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-4.
148. Koup RA, Pikora CA, Mazzara G, Panicali D, Sullivan JL. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol 1991;4:215-23.
149. Dadaglio G, Michel F, Langlade-Demoyen P, et al. Enhancement of HIV-specific cytotoxic T lymphocyte responses by zidovudine (AZT) treatment. Clin Exp Immunol 1992;87:7-14.
150. Dailey MO, Pillemer E, Weissman IL. Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc Natl Acad Sci USA 1982;79:5384-7.
151. Ruprecht RM, Mullaney S, Bernard LD, Gama Sosa MA, Hom RC, Finberg RW. Vaccination with a live retrovirus: the nature of the protective immune response. Proc Natl Acad Sci USA 1990; 87:5558-62.
152. Engers HD, Lahaye T, Sorenson GD, Glasebrook AL, Horvath C, Brunner KT. Functional activity in vivo of effector T cell populations. II. Antitumor activity exhibited by syngeneic anti-MoMULVspecific cytolytic T cell clones. J Immunol 1984;133:1664-70.
153. van der Hoorn FA, Lahaye T, Milner V, Ogle MA, Engers HD. Characterization of gP8 5gag as an antigen recognized by Moloney leukemia virus-specific cytolytic T cell clones that function in vivo. J Exp Med 1985;162:128-44.
154. Lehmann-Grube F, Moskophidis D, Uhler J. Recovery from acute virus infection: role of cytotoxic T lymphocytes in the elimination of lymphocytic choriomeningitis virus from spleens of mice. Ann N Y Acad Sci 1988;532:238-56.
155. Klavinskis LS, Whitton JL, Joly E, Oldstone MB. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology 1990;178:393-400.
156. Kast WM, Offringa R, Peters PJ, et al. Eradication of adenovirus Elinduced tumors by E1A-specific cytotoxic T lymphocytes. Cell 1989;59:603-14.
157. Reddehase MJ, Jonjie S, Weiland F, Mutter W, Koszinowski UH. Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors. J Virol 1988;62:1061-5.
158. Mosier DE, Gulizia RJ, Maclssac P, Torbett BE, Corey L, Greenberg P. Prevention of HIV-1 infection in hu-PBL-SCID mice [abstract no Q014]. J Cell Biochem 1992;suppl 16E:6.
159. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokineactivated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
160. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-8.
161. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-41.
162. Ho M, Armstrong J, McMahon D, et al. A phase 1 study of adoptive transfer of autologous CD8 ± T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. Blood 1993;81:2093-101.
163. Klimas NG, Fletcher MA, Walling J, et al. Phase I trial of adoptive immunotherapy with purified CD8 cells in HIV infection [abstract no PoB3446]. In: Program and abstracts: VIII International Conference on AIDS (Amsterdam). Amsterdam: Congrex Holland BV, 1992.
164. Koenig S, van Kuyk R, Jones G, et al. Adoptive transfer of a nef-specific CTL clone into hu-PBL-SCID mice and an HIV-infected patient [abstract no ThA1573]. In: Program and abstracts: VIII International Conference on AIDS (Amsterdam). Amsterdam: Congrex Holland BV, 1992.
165. Koenig S, Jones G, Boone E, et al. Inhibition of HIV replication by HIV-specific CTL [abstract no TU.A.80]. In: Program and abstracts: VII International Conference on AIDS (Florence). Rome: Instituto Superiore di Sanita, 1991.
166. Lieberman J, Fabry JA, Kuo M-C, Earl P, Moss B, Skolnik PR. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in gp160 and reverse transcriptase. J Immunol 1992;148:2738-47.
167. Hosmalin A, Clerici M, Houghten R, et al. An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1990;87:2344-8.
168. Lane HC, Zunich KM, Wilson W, et al. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;113:512-9.
169. Holland HK, Saral R, Rossi JJ, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection: studies in a patient with non-Hodgkin lymphoma. Ann Intern Med 1989;111:973-81.
170. Gerberding JL, Henderson DK. Management of occupational exposures to bloodborne pathogens: hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Clin Infect Dis 1992; 14:1179-85.
171. Autran B, Plata F, Guillon JM, Joly P, Mayaud C, Debre P. HIV-specific cytotoxic T lymphocytes directed against alveolar macrophages in HIV-infected patients. Res Virol 1990;141:131-6.
172. Sethi KK, Miler H, Stroehmann I. Phenotypic heterogeneity of cerebrospinal fluid-derived HIV-specific and HLA-restricted cytotoxic T-cell clones. Nature 1988;335:178-81.
173. Lanzavecchia A, Roosnek E, Gregory T, Berman P, Abrignani S. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature 1988;334:530-2.
174. Bumstead FJ. The treatment of syphilis by repeated inoculations of matter derived from venereal sores: so-called syphilization. Am J Med Sci 1870;60:2-36.
175. Dr. Koch's investigations upon the treatment of tuberculosis. Lancet 1890;2:932-3.
176. Wright AE. Notes on the treatment of furunculosis, sycosis, and acne by the inoculation of a staphylococcus vaccine, and generally on the treatment of localised bacterial invasions by therapeutic inoculations of the corresponding bacterial vaccines. Lancet 1902;1:874-84.
177. Zaheer SA, Mukherjee R, Ramkumar B, et al. Combined multidrug and Mycobacteria w vaccine therapy in patients with multibacillary leprosy. J Infect Dis 1993;167:401-10.
178. Botarelli P, Houlden BA, Haigwood NL, Servis C, Montagna D, Abrignani S. N-Glycosylation ofHIV-gp-120 may constrain recognition by T lymphocytes. J Immunol 1991;147:3128-32.
179. Browning M, Reid G, Osborne R, Jarrett 0. Incorporation of soluble antigens into ISCOMS: HIV gp120 ISCOMs induce virus neutralizing antibodies. Vaccine 1992;10:585-90.
180. Akerblom L, Nara P, Dunlop N, Morein B. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response. AIDS Res Hum Retroviruses 1991;7:621-7.
181. Glaser JB, Volpe S, Aguirre A, Simpkins H, Schiffman G. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J Infect Dis 1991;164:761-4.
182. Haubrich RH, Takeda A, Koff W, Smith G, Ennis FA. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp-160 experimental HIV-1 vaccine. J Infect Dis 1992;165:545-8.
183. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4 + T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992;175:331-40.
184. Zagury D, Bernard J, Halbreich A, et al. One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy. J Acquir Immun Defic Syndr 1992;5:676-81.
185. Redfield RR, Birx DL, Ketter N, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991;324:1677-84.
186. Cheingsong-Popov R, Callow D, Beddows S, et al. Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization. J Infect Dis 1992;165:256-61.
187. Valentine F, Katzenstein D, Haslett P, et al. A randomized controlled study of immunogenicity of rgp160 vaccine in HIV infected subjects [abstract no TuB 0561]. In: Program and abstracts: VIII International Conference on AIDS (Amsterdam). Amsterdam: Congrex Holland BV, 1992.
188. Haffar O, Moran PA, Smithgall MD, et al. Inhibition of virus production in peripheral blood mononuclear cells from human immunodeficiency virus (HIV) type-1 seropositive donors by treatment with recombinant HIV-like particles. J Virol 1992;66:4279-87.
189. Kr5usslich H-G, Ochsenbauer C, Traenckner A-M, et al. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology 1993;192:605-17.
190. Martin S, Weber J, Roitt I, Matear P, Jones K, Vyakarnam A. Recombinant HIV-1 gag p24-TY virus like particles (VLP's) induce HIV-1 p24 specific helper cells in seronegative volunteers vaccinated with these particles [abstract no PoA 2194]. In: Program and abstracts: VIII International Conference on AIDS (Amsterdam). Amsterdam: Congrex Holland BV, 1992.
191. Hart MK, Palker TJ, Matthews TJ, et al. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol 1990;145:2677-85.
192. Wilks D, Walker LC, Habeshaw JA, Webster ADB, Dalgleish AG. Antiidiotypic responses to immunization with anti-Leu 3a in human immunodeficiency virus-seropositive individuals. J Infect Dis 1991;163:389-92.
193. Robert-Guroff M, Reitz MS, Robey WG, Gallo RC. In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol 1986;137:3306-9.
194. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:453-9.
195. Reitz MS, Wilson C, Naugle C, Gallo RC, Robert-Guroff M. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 1988;54:57-63.